Immunicum AB announced today that the United States Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug application (IND) for INTUVAX. The IND clearance enables Immunicum to expand its ongoing Phase II study – MERECA (MEtastatic REnal Cell CArcinoma) – for the treatment of metastatic renal cell cancer patients, into the United States.
Notice: Theme without comments.php is deprecated since version 3.0.0 with no alternative available. Please include a comments.php template in your theme. in /home/i/immunicu/www/wp-includes/functions.php on line 4805